“This event is an Accredited Group Learning Activity as defined by the CSCC/CACB Professional Development Program.”
« Cette activité est une activité de formation collective agréée selon la définition établie par le Programme de perfectionnement professionnel de la SCCC et l’ACBC. »

  Thursday August 13, 2020

1200-1345 EDT

Symposium 4: Critical Updates in Laboratory Medicine

 Chair: Uvaraj Uddayasankar, Clinical Biochemist, LifeLabs, Mississauga, ON
1200 Welcome
1205 Updates in allergen-specific IgE testing
Speaker: Alex Chin, Clinical Chemist, Alberta Precision Laboratories, University of Calgary, Calgary, AB
Objectives: At the end of the session, participants will be able to:
1. Summarize the pathophysiology of the allergic reaction
2. Discuss the role of laboratory measurement of allergenspecific IgE
3. Discuss the future directions of laboratory allergy diagnostics
Overview: The allergic response is characterized by the breakdown of immune tolerance and subsequent initiation of allergic sensitization and allergic response. A key feature of the allergic response is the production of allergen-specific IgE by B cells. While the diagnosis of allergy is multifactorial, the measurement of serum allergen-specific IgE has specific indications over the gold standard skin prick testing such as interfering medications, skin conditions, and avoidance of allergen exposure due to previous reactions. Furthermore, measurement of serum allergen-specific IgE has grown in prominence due to increased access to testing by primary care providers and lengthening wait times to allergy specialists. The methods to measure allergen-specific IgE have been mainly based using whole extracts or whole recombinant preparations. However, allergen-specific IgE testing is evolving to include measurement of molecular components for more specific diagnosis, particularly for life-threatening anaphylaxis. This presentation will summarize the basic principles of the allergic response, and discuss the current role and future directions of the clinical laboratory in the diagnosis of allergy.

The session will be of value to clinical chemists, pathologists, laboratory directors, technologists, assistants, trainees, and in vitro diagnostics industry professionals.

1225 Autoimmune Testing
Speaker:  Ron Booth, Associate Professor & Clinical Biochemist, University of Ottawa, Ottawa Hospital & EORTA, Ottawa ON
Objectives:  At the end of the session participants will be able to:
1. Recognize laboratory testing useful in common autoimmune conditions
2. Identify current autoimmune diagnostic testing recommendations
3. Summarize optimal autoimmune testing panels
Overview:  This session will provide laboratorians not intimately familiar with autoimmune and immunology diagnostics with an overview of the current recommended tests useful in common autoimmune conditions. The appropriate use of testing panels and/or multiple biomarkers markers will be highlighted. The session will be of value to Clinical/Medical Biochemists, Trainees, Technologists, Laboratory Managers and anyone associated with autoimmune testing.
1245  Mass Spectrometry for Clinical Biochemistry 
Speaker:  Dennis Orton, Clinical Biochemist, Alberta Precision Labs, Calgary AB
Objectives:  At the end of the session participants will be able to:
1. Understand some key quality indicators in Clinical LC-MS
2. Appreciate the direction that Clinical LC-MS is heading and how that impacts lab oversight
3. Recognize the importance of monitoring LC-MS lab data quality

Over the past few decades, Liquid Chromatography-Mass Spectrometry (LC-MS) methodology has become firmly entrenched in the clinical laboratory. As advancements are made in more user-friendly software and commercially available kit methods become available, MS technologies are poised to expand beyond reference laboratories and into the more routine clinical areas. In fact, with imminent expansion to the fields of anatomic pathology, hematology, and point of care, it is more important than ever for laboratory staff and leadership to have a fundamental understanding of MS technology, but more importantly relevant quality metrics, and troubleshooting strategies to allow us to move forward into the future of the clinical laboratory.

Discussion will cover the current state of LC-MS in the clinical laboratory and address the use of commercially available kit methods with regards to accreditation requirements and quality metric monitoring (e.g. system suitability samples, QC and calibrator preparation, lot-to-lot validations, enzymatic digestion or hydrolysis efficiency). The focus of this talk is not on how the LC-MS system functions, but rather what metrics are important to track when validating a new LC-MS method and when monitoring the quality of your assays over time. As LC-MS technology expands, those who oversee routine testing labs will be called upon to help monitor and troubleshoot these assays the same as any other, and it is important for us to arm ourselves with knowledge so that we may continue generating high quality results for optimal patient care.

This session will be of value to those who are involved in oversight of the clinical laboratory and instrument selection, plus those who oversee the quality of lab data, including Clinical Biochemists, Fellows and Residents.

1305  Cancer Biomarkers
Speaker: Qing H. Meng, Ph.D., DABCC, FCACB, Professor and Section Head, The University of Texas MD Anderson Center, Houston TX
Objectives: At the end of the session participants will be able to:
1. Discuss the current status and clinical application of tumor markers;
2. Identify emerging tumor biomarkers in oncology
Overview: Tumor markers are being used by clinicians for cancer screening, diagnostic aids, therapeutic monitoring, surveillance, and prognosis assessment. Though the use of tumor markers is extensive in clinical practice, there are limitations and challenges with the utility of tumor markers. With the advances of new technologies, new biomarkers are being discovered and validated for clinical service. They are evolving into new roles in the era of personalized cancer medicine.
1325 Educational Recommendations on Cardiac Biomarkers: an update from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers
Speaker:  Peter Kavsak, McMaster University & Member on IFCC Committee on Clinical Applications of Cardiac Bio-Markers, Hamilton ON
Objectives: At the end of the session participants will be able to:
1. Apply the IFCC C-CB laboratory recommendations to both natriuretic peptide testing and cardiac troponin in their laboratory
2. Develop an approach to minimize inappropriate testing and reporting for cardiac troponin and the natriuretic peptide tests.
Overview: The IFCC Committee on Clinical Applications of Cardiac Bio-Markers (IFCC C-CB) has mandate on providing education on establish and novel cardiac biomarkers. In this workshop the two most recent recommendations (2019 & 2018) will be discussed with examples on how to implement laboratory recommendations:
1. Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers
2. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine.